European Companies Search Engine

Quick Search Power Search
Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

8 EU fundings (€450,000): Modern approaches for developing antivirals against SARS-CoV 2 … BdlYear 2020 EU Research and Innovation programme "Horizon"

Text

Inserm Transfert SA, Paris, France

01/07/2020 EU funding (€240,938): European Research and Preparedness Network for Pandemics and Emerging Infectious Diseases
01/01/2020 EU funding (€247,875): FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA
01/08/2020 EU funding (€249,875): Modern approaches for developing antivirals against SARS-CoV 2
01/01/2020 EU funding (€300,000): Immune profiling to guide host-directed interventions to cure HBV infections
01/01/2020 EU funding (€324,563): Brain injury in the premature born infant: stem cell regeneration research network
01/01/2020 EU funding (€390,993): Associative mechanisms linking a defective minipuberty to the appearance of mental and nonmental disorders: infantile NO replenishment as a new therapeutic possibility
01/01/2020 EU funding (€442,165): Impact of exposome on the course of lung diseases
01/04/2020 EU funding (€450,000): Corona Accelerated R&D in Europe

DATA SERVICES

Unlock the full potential of processed company data with our API or Quarterly Exports.

This filing was translated from to English. The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Inserm Transfert SA, Paris, France.

Creative Commons License The visualizations for "Inserm Transfert SA - 8 EU fundings (€450,000): Modern approaches for developing antivirals against SARS-CoV 2 …" are provided by North Data and may be reused under the terms of the Creative Commons CC-BY license.

Printing is only available to North Data premium service subscribers.
Close